Table 2.
Bound limits of biological and therapeutic parameters applicable to human cases
Parameter | Lower limit | Upper limit | Reference |
---|---|---|---|
Circulating Lymphocyte, C (total population in the individual) |
2.32 × 109 cells (for not more than 6 months duration) |
4.5 × 1011 cells |
Macintyre et al.[26] (upper limit); Jarosz et al.[27] (lower limit) |
Natural Killer Cells, N (total population in the individual) |
Negligible value (for not more than 3½ months duration) |
5.85 × 1010 cells |
Berrington et al.[28] (upper limit); Jawahar et al.[29] (lower limit) |
Tumour-specific cytotoxic (CD8+) T-cells (CTL), L (total population of these cells in the individual) |
Negligible value * |
6.05 × 1010 cells |
Dudley et al.[25] (upper limit); Roitt et al.[30] (lower limit) |
Temozolomide infusion dosage rate, vM |
0 |
200 mg/m2/day (4.45mg/kg/day) |
Perry [1] |
Interleukin-2 infusion dosage rate, v
I
|
0 |
7.2 × 104 I.U/kg/day |
Perry [1] |
Tumour Infiltrating lymphocyte (TIL) cumulative dosage (over full therapy duration, i.e., ∑ v L ) | 0 | 13.7 × 1010 cells | Dudley et al.[25] |
* This is applicable to the time after the tumour has been eliminated and pertains to population of the effective CD8+ T-cells specifically active against the particular tumour-lesion in the body; after tumour elimination, there is no possibility of stimulation by tumour cells to initiate the generation of the active tumour-specific CTL. The various bound values in the Table can be relaxed by 10-15%, this relaxation in the limits of physiological parameters being accommodated by the homeostatic adaptation of the physiological system [31]. Note: For clarifications of values of the bounds, see endnote a before the references bibliography.